<DOC>
	<DOCNO>NCT02170090</DOCNO>
	<brief_summary>This multicentre , prospective , randomize , control phase III trial design assess clinical performance gemcitabine cisplatin observation vs. observation alone patient curative intent resection cholangiocarcinoma muscle invasive gall bladder carcinoma .</brief_summary>
	<brief_title>Adjuvant Chemotherapy With Gemcitabine Cisplatin Compared Observation After Curative Intent Resection Biliary Tract Cancer</brief_title>
	<detailed_description>The ACTICCA-1 investigator initiate trial fund Deutsche Krebshilfe ( grant number 110215 ) support medac . With respect data obtain ABC-02 trial , combination cisplatin gemcitabine 24 week investigational treatment select . Based adjuvant trial pancreatic cancer ( e.g . ESPAC IV ) comparable postoperative recovery time , inclusion patient within maximum interval 16 week surgery start CTx chosen . Due different prognosis treatment susceptibility muscle invasive carcinoma , two separate cohort CCA GBCA include capture expect treatment effect . Randomization stratify lymph node status cohort localization CCA . The primary endpoint DFS secondary endpoint include OS , safety tolerability adjuvant CTx , quality life , pattern disease recurrence . In cohort , randomization 1:1 adjuvant CTx 24 week image every 12 week experimental arm observation control arm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>All enrol patient postoperatively assessed eligibility treatment phase . Additionally patient previously enrol trial whatever reason ( e.g . incidental finding surgery ) evaluate eligibility . Histologically confirm adenocarcinoma biliary tract ( intrahepatic , hilar extrahepatic cholangiocarcinoma muscle invasive gallbladder carcinoma ) radical surgical therapy macroscopically complete resection ( mixed tumor entity ( HCC/CCA ) exclude ) Macroscopically complete resection ( R0/1 ) within 6 ( 16 ) week schedule start chemotherapy ECOG 01 Age &gt; 18 year Adequate hematologic function Adequate liver function Adequate renal function No active uncontrolled infection , except chronic viral hepatitis antiviral therapy No concurrent treatment experimental drug anticancer therapy , treatment clinical trial within 30 day prior randomization Negative serum pregnancy test within 7 day start study treatment premenopausal woman woman &lt; 1 year onset menopause ( Note : negative test reconfirm urine test , 7day window exceed ) Criteria initial study enrolment Written inform consent No prior chemotherapy cholangiocarcinoma No previous malignancy within 3 year concomitant malignancy , except : nonmelanomatous skin cancer adequately treat situ cervical cancer No severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , unstable angina pectoris , history myocardial infarction last 3 month , significant arrhythmia ) Absence psychiatric disorder preclude understanding information trial related topic give informed consent No serious underlie medical condition ( judge investigator ) , could impair ability patient participate trial Fertile woman ( &lt; 1 year last menstruation ) procreative men willing able use effective mean contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly surgically sterile ) No pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>muscle invasive gall bladder carcinoma</keyword>
	<keyword>translational research</keyword>
	<keyword>multidisciplinary</keyword>
	<keyword>AIO , DGAV , DGVS</keyword>
</DOC>